Senhwa Biosciences, Inc.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
CX-4945 in Viral Community Acquired Pneumonia
- Conditions
- Community-acquired PneumoniaSARS-CoV-2 -Associated PneumoniaInfluenza With Pneumonia
- Interventions
- Drug: CX-4945 (SARS-CoV-2 domain)Drug: Placebo (SARS-CoV-2 domain)Drug: Placebo (Influenza virus domain)Drug: CX-4945 (Influenza virus domain)
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06202521
- Locations
- 🇨🇳
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
🇨🇳Far Eastern Memorial Hospital, New Taipei City, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
A Study of Silmitasertib (CX-4945) in Healthy Subject
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05817708
- Locations
- 🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04890613
- Locations
- 🇺🇸
University of California, Los Angeles, Santa Monica, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04663737
- Locations
- 🇺🇸
Center for Advanced Research and Education, Gainesville, Georgia, United States
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03897036
- Locations
- 🇺🇸
HonorHealth Research & Innovation Institute, Scottsdale, Arizona, United States
🇺🇸Texas Oncology, P.A., Dallas, Texas, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Prev
- 1
- 2
- Next
News
Silmitasertib Trial Launched for Childhood Solid Tumors
A clinical trial is underway to assess silmitasertib combined with chemotherapy for treating solid tumors in children and young adults.